Topiramate or flunarizine in the preventive treatment of migraine. A comparative study of two series of cases;Topiramato o flunaricina en el tratamiento preventivo de la migraña. Estudio comparativo de dos series de casos

Revista de Neurologia

Volumn 41, Issue 12, 2005, Pages 705-708

  Gracia Naya, Manuel ^a   Latorre Jimenez A M ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Flunarizine; Headache; Migraine; Migraine prophylaxis; Topiramate; Treatment of migraine

Indexed keywords

FLUNARIZINE; TOPIRAMATE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; FRUCTOSE;

AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; PROPHYLAXIS; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT; ADULT; COMPARATIVE STUDY; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; FEMALE; FLUNARIZINE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; TREATMENT OUTCOME;

EID: 33644845521     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4112.2005445     Document Type: Article

References (35)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646-57.
2. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002; 58: 885-94.
3. Gracia-Naya M. Impacto y diferencias asistenciales de la migraña con o sin aura en las consultas de neurología. Neurología 1999; 14: 383-8.
4. Morgenstern LB, Huber JC, Luna-Gonzales H, Saldin, HR, Grotta JC, Shaw SG, et al. Headache in the emergency department. Headache 2001; 41: 537-41.
5. Jiménez-Caballero PE. Análisis de las cefaleas atendidas en las guardias de Neurología. Rev Neurol 2005; 40: 648-51.
6. Laml C, Buzath A, Yazdi K, Sandor PS. Ergot and triptan overuse in Austria: an evaluation of clinical data and cost. Cephalalgia 2002; 22: 807-11.
7. Gracia-Naya M, Latorre A, García de Pablo MS. Valoración de los pacientes con migraña enviados a una unidad de cefaleas. Neurología 2001; 16: 446-7.
8. Ferrari MD. Migraine. Lancet 1998; 351: 1043-51.
9. Láinez JM, López A, Pascual AM. Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study. Headache 2005; 457: 883-90.
10. Katsarava Z, Schneeweiss S, Kurth T, Kroener U, Fritsche G, Eikermann A, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004; 62: 788-90.
11. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global migraine and zolmitriptan evaluation survey. Headache 2003; 43: 19-26.
12. Gracia-Naya M, Latorre-Jiménez AM. Diferencias entre los pacientes con migraña enviados a una unidad de cefaleas o a una consulta general de neurología. Rev Neurol 2003; 37: 521-4.
13. Silberstein SD, Goadsby P. Migraine: preventive treatment. Cephalalgia 2002; 22: 491-512.
14. Limmroth V, Michel MC. The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001; 52: 237-43.
15. Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991; 31: 333-40.
16. Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia 1984; 4: 91-6.
17. Forssman B, Lindblad CJ, Zhornikova V. Atenolol for migraine prophylaxis. Headache 1983; 23: 188-90.
18. Freitag FG, Diamond S. Nadolol and placebo comparison study in the prophylactic treatment of migraine. J Amer Osteopath Assoc 1984; 84: 343-7.
19. Ziegler DK, Hurwitz A, Preskom S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine. Arch Neurol 1993; 50: 825-30.
20. Diener HC, Matías-Guíu J, Hartung E, Pfaffenrath V, Ludin HP, Nappi G, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced dosis: a comparison with propranolol 160 mg daily. Cephalalgia 2002; 22: 209-21.
21. Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci 1992; 19: 340-5.
22. Reveiz-Herault L, Cardona AF, Ospina EG, Carrillo P. Eficacia de flunaricina en la profilaxis de la migraña: revisión metaanalítica de la bibliografía. Rev Neurol 2003; 36: 907-12.
23. Freitag FG, Collins S, Carlson H, Goldstein J, Saper J, Silberstein S, et al. Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58: 1652-9.
24. Mathew NT, Saper IR, Silberstein SD, Rankin L, Markley HG, Solomon S, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52: 281-6.
25. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate for migraine prevention. A randomized controlled trial. JAMA 2004; 291: 965-73.
26. Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61: 490-5.
27. Diener HC, Tfet-Hansen P, Dahloff C, Láinez MJ, Sandrini G, Wang ShJ, et al. Topiramate in migraine prophylaxis. Results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251: 943-50.
28. Headache Classification Committee of International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8: 1-96.
29. Silberstein SD, Lipton RB, Solomon S, Mattew N. Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache 1994; 34: 17.
30. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near daily headaches: field trial of revised IHS criteria. Neurology 1996; 47: 871-5.
31. Bland JM, Altman DG. One and two sided tests of significance. BMJ 1994; 309: 248.
32. Gracia-Naya M, Latorre A. Efectividad de topiramato en la profilaxis de la migraña. Estudio observacional en una serie consecutiva de casos. Neurología 2005; 20: 225-31.
33. Lara M, Díez-Tejedor E. Antagonistas del calcio en la profilaxis de la migraña. Rev Neurol 1995; 23 (Supl 2): S179-84.
34. Martín R, Kuzniecky R, Ho S, Hetherungton H, Pan J, Sinclair K, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999; 52: 321-7.
35. Jones MW. Topiramate: safety and tolerability. Can J Neurol Sci 1998; 25: 13-5.